[go: up one dir, main page]

IL161832A0 - Pharmaceutical composition for inducing an immune response in a human or animal - Google Patents

Pharmaceutical composition for inducing an immune response in a human or animal

Info

Publication number
IL161832A0
IL161832A0 IL16183202A IL16183202A IL161832A0 IL 161832 A0 IL161832 A0 IL 161832A0 IL 16183202 A IL16183202 A IL 16183202A IL 16183202 A IL16183202 A IL 16183202A IL 161832 A0 IL161832 A0 IL 161832A0
Authority
IL
Israel
Prior art keywords
inducing
animal
human
immune response
pharmaceutical composition
Prior art date
Application number
IL16183202A
Other languages
English (en)
Original Assignee
Dandrit Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dandrit Biotech As filed Critical Dandrit Biotech As
Publication of IL161832A0 publication Critical patent/IL161832A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16183202A 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal IL161832A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101770 2001-11-29
US33670601P 2001-12-07 2001-12-07
PCT/DK2002/000802 WO2003045427A2 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Publications (1)

Publication Number Publication Date
IL161832A0 true IL161832A0 (en) 2005-11-20

Family

ID=26069102

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16183202A IL161832A0 (en) 2001-11-29 2002-11-29 Pharmaceutical composition for inducing an immune response in a human or animal

Country Status (11)

Country Link
US (2) US7771998B2 (xx)
EP (1) EP1448229B1 (xx)
JP (1) JP2005515192A (xx)
AT (1) ATE446106T1 (xx)
AU (1) AU2002365291B2 (xx)
DE (1) DE60234115D1 (xx)
DK (1) DK1448229T3 (xx)
ES (1) ES2335396T3 (xx)
IL (1) IL161832A0 (xx)
RU (1) RU2313365C2 (xx)
WO (1) WO2003045427A2 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ES2294346T3 (es) * 2002-11-28 2008-04-01 Peter Kufer Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage.
DE602005027407D1 (de) * 2004-11-18 2011-05-19 Univ Hiroshima Nat Univ Corp Verfahren und Kit zur Proteinexpression und Regelung der Expression wiederholter Sequenzen, die durch Genamplifikation und -transformierung gebildet werden
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
BRPI0706784A2 (pt) 2006-01-30 2011-04-05 Ludwig Inst Cancer Res antìgeno de cáncer de testìculo ctsp
GB0612342D0 (en) 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy
CN101755045B (zh) 2007-05-17 2014-02-12 生物载体株式会社 树突状细胞的制备方法
EP2318040A4 (en) * 2008-07-24 2013-05-01 Univ Central Florida Res Found THERAPY TREATED ON CANCER STAMPS
BRPI0920679A2 (pt) * 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
RU2012111349A (ru) 2009-08-24 2013-10-27 Байлор Колледж Оф Медсин Генерация линий ctl со специфичностью против множества опухолевых антигенов или множества вирусов
KR20130010121A (ko) * 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
GB201013443D0 (en) * 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
JP6038921B2 (ja) 2011-08-30 2016-12-07 アステックス ファーマシューティカルズ インコーポレイテッド デシタビン誘導体製剤
AU2012325758A1 (en) * 2011-10-20 2014-04-24 Neostem Oncology, Llc Antigen presenting cancer vaccine with gamma interferon
JP5871228B2 (ja) * 2011-10-31 2016-03-01 国立大学法人佐賀大学 慢性副鼻腔炎の検出方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
DK2812431T3 (da) 2012-02-09 2019-10-14 Baylor College Medicine Peptidblandinger til generering af multivirale ctl'er med bred specificitet
WO2014007669A1 (ru) * 2012-07-04 2014-01-09 Volgushev Sergei Anatolievich Аутологичная клеточная вакцина для лечения онкологических заболеваний и способ ее получения
MX2018000016A (es) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Composiciones farmaceuticas liofilizadas.
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
GB201520542D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
MX2021000421A (es) 2018-07-15 2021-05-12 Enochian Biopharma Inc Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer.
EP3903811A1 (en) 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmaceutical composition and method for inducing an immune response
EP3981425A1 (en) 2020-10-12 2022-04-13 R.G.C.C. Holdings AG Sars-cov-2 vaccines
CA3119597C (en) 2020-10-12 2023-07-11 R.G.C.C. Holdings AG Sars-cov-2 vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
AU2087401A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
EP2149381A3 (en) 2001-03-09 2010-05-05 Baylor Research Institute Method of treating malignancies through induction of blood immune responses

Also Published As

Publication number Publication date
WO2003045427A2 (en) 2003-06-05
US20060051324A1 (en) 2006-03-09
US7771998B2 (en) 2010-08-10
EP1448229B1 (en) 2009-10-21
ES2335396T3 (es) 2010-03-26
ATE446106T1 (de) 2009-11-15
JP2005515192A (ja) 2005-05-26
RU2004119548A (ru) 2005-03-27
DE60234115D1 (de) 2009-12-03
HK1086750A1 (zh) 2006-09-29
US20090029457A1 (en) 2009-01-29
DK1448229T3 (da) 2010-03-08
AU2002365291A1 (en) 2003-06-10
RU2313365C2 (ru) 2007-12-27
EP1448229A2 (en) 2004-08-25
WO2003045427A3 (en) 2004-03-25
US7723107B2 (en) 2010-05-25
AU2002365291B2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
IL172700A0 (en) Compositions and methods for regulating nk cell activity
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
NZ306653A (en) Isolated dna il-17 receptors
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
PT1331944E (pt) Utilização de anticorpos monoclonais específicos para cd28 para a estimulação de células sanguíneas que não comportam qualquer cd28
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
EP4249075A3 (en) Methods of administering chimeric antigen receptor immunotherapy
WO2002010350A1 (en) Method of proliferating natural killer cells
WO2004012681A3 (en) Cancer vaccines containing epitopes of oncofetal antigen
AU2599002A (en) Fusion cells and cytokine compositions for treatment of disease
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
AU8026800A (en) Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
WO2002091996A3 (en) Methods for treating cancer
ATE412763T1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
WO2000073432A3 (en) Activation of dendritic cells to enhance immunity
MY127452A (en) Vaccines.